2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Animal Model
PAPER

4132 Monocyte-derived soluble MILR1 is associated with severe cytokine release syndrome and delays CAR T-cell killing of B-ALL cells

Marie Juzans, PhD, Madison Hannan2, Apoorva Babu3, Anastasia Frank-Kamenetskii4, Hannah Klinghoffer5, Lahari Uppuluri, PhD6, Zachary Martinez7, Andrew Hughes, MD, PhD8, Thomas Manley9, Jennifer Roof10, Hossein Fazelinia11, Lynn Spruce12, Joseph Fraietta, PhD13, Marco Ruella, MD14, Luca Paruzzo, MD15, Mohannad H Alkhatib16, David T. Teachey, MD17, Amanda DiNofia, MD18, Shannon L. Maude, MD19, Regina M. Myers, MD20, Allison Barz Leahy, MD, MSCE21, Stephan A Grupp, MD, PhD22, Scott Canna23, Caroline Diorio, MD24
1 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
2 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
3 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
4 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
5 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
6 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
7 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
8 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
9 University of Pennsylvania, Philadelphia, Pennsylvania, United States
10 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
11 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
12 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
13 University of Pennsylvania, Philadelphia, Pennsylvania, United States
14 University of Pennsylvania, Philadelphia, Pennsylvania, United States
15 University of Pennsylvania, Philadelphia, Pennsylvania, United States
16 University of Pennsylvania, Philadelphia, Pennsylvania, United States
17 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
18 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
19 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
20 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
21 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
22 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
23 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
24 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Introduction

Cytokine release syndrome (CRS) is the most common severe adverse event following chimeric antigen receptor T-cell (CART) therapy for B-cell acute lymphoblastic leukemia (B-ALL) and other hematologic malignancies. High disease burden (bone marrow blasts ≥25%) before infusion is the best characterized risk factor for severe CRS (ASTCT Grade ≥3).

We previously identified Mast Cell Immunoglobulin-like Receptor 1 (MILR1) as a pre-infusion serum biomarker of severe CRS risk in pediatric B-ALL patients (35705524). MILR1 is inhibits mast cell degranulation in allergic reactions. Its role in CRS remains unknown. In this study, we evaluate MILR1 as a pre-infusion biomarker, identify its cellular source, and investigate its potential role in mediating severe CRS.

Methods

Soluble MILR1 was measured by Olink proximity extension assay in the serum of patients from 3 separate cohorts pre-CART infusion: adult patients with lymphoma, with other hematologic malignancies (B-ALL, multiple myeloma, chronic lymphocytic leukemia), and pediatric B-ALL patients with high disease burden (DB).

Single Cell RNA sequencing was performed on PBMCs from pediatric patients with B-ALL to identify the cellular source of MILR1.

Functional in vitro assays utilized CART19 cells, NALM6 B-ALL cell line, and healthy donor PBMCs. Surface MILR1 was quantified by flow cytometry; soluble MILR1 and IFN-γ were measured by ELISA. Phosphoproteomics using liquid chromatography-tandem mass spectrometry was used to identify signaling pathways regulated by MILR1. CART19 cytotoxicity was assessed by cell viability assays and by live-cell confocal microscopy.

Results

In adults with lymphoma (N=90) or other hematologic malignancies (N=24), serum MILR1 levels measured pre-infusion correlated with DB and were higher in patients who developed severe versus minimal CRS (p=0.046 and p=0.015, respectively).

In pediatric B-ALL patients who had high DB (N=81), DB did not differ between patients who developed severe vs minimal CRS (median 80% vs 85%, p=0.95). In contrast, MILR1 levels were higher in patients who developed severe versus minimal CRS (median normalized protein expression 0.81 vs. -0.2, p=0.03). 

MILR1 mRNA was detected in monocytes (median log-normalized expression 0.61), B cells (0.66), and lymphoblasts (0.59) from patient with B-ALL. Cell-surface expression of MILR1 was confirmed on NALM6 cells, B cells, monocytes and monocyte-derived macrophages by flow cytometry.  Soluble MILR1 was detected in culture supernatants from monocytes (2.7 ng/mL) and pro-inflammatory M1-like macrophages (0.3 ng/mL) but not lymphoblasts, B cells, undifferentiated M0- or anti-inflammatory M2-like macrophages.

Functionally, the preincubation of NALM6 cells with recombinant MILR1 (10 ng/mL) resulted in a delay in their killing by CART19. Observation by live-cell microscopy of immune synapses formed between NALM6 cells and CART19 revealed prolonged median killing process duration (10.2 vs 6.1 min, p=0.03). Co-culture supernatants showed increased CART19 IFN-γ secretion (10.7 vs 8.8 ng/mL, p=0.01). Together, these results suggest that soluble MILR1 reduces NALM6 cells susceptibility to CART killing. In contrast, preincubation of CART19 with MILR1 showed no significant effects.

To investigate the effect of MILR1 on lymphoblast signaling, we performed phosphoproteomics on NALM6 cells preincubated with MILR1. Kinase enrichment analysis revealed increased activity of pathways involving STAT3, NFkB, and mTOR. Phospho-flow cytometry confirmed increased phosphorylation of STAT3 and mTOR, but not NFkB. Notably, NALM6 cells cultured with MILR1 for 24-72 hours did not proliferate more than untreated cells.

Discussion

We demonstrate that pre-infusion soluble MILR1 predicts severe CRS risk across hematologic malignancies, including in a high DB cohort in which DB no longer distinguished CRS severity.

Monocytes and pro-inflammatory macrophages are sources of soluble MILR1. Elevated serum MILR1 may promote immune resistance in lymphoblasts through STAT3 activity, prolonging time necessary to kill tumor cells, and resulting in increased secretion of IFN-γ, potentially leading to increased CRS severity.

Ongoing studies aim to further define MILR1-mediated pathways in lymphoblasts and determine whether MILR1 directly contributes to CRS. Future investigations will test whether MILR1 blockade can mitigate severe CRS in at-risk patients.

Marie Juzans, PhD: No relevant conflicts of interest to declare.